Dapagliflozin prevents kidney function decline in T2D
Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk
Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (Pinteraction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).
Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.
,Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.
Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382